TNFRSF17 and Miyoshi myopathy: CD3 molecules deliver the first activation signal to T cells, and previous studies showed that IBI379 can effectively target TNFRSF17 and CD3, and inducing T cell activation, proliferation, and clearance of TNFRSF17+ plasma cells in multiple myeloma (MM) patients (35).